Interpore Is Seeking SEC Approval for $20-Million Public Stock Offering
- Share via
IRVINE — Interpore International, a developer of synthetic bone graft material, is seeking permission to go public with the sale of up to $20 million worth of common stock.
In a filing with the Securities and Exchange Commission, the company said proceeds of the public offering of 2 million shares, to be priced at $8 to $10 a share, would be used to repay debt, fund clinical studies and research and development, and possibly to finance acquisitions.
Of the total shares, 500,000 would be offered by existing shareholders and 1.5 million would be sold by the company. Prudential Securities Inc., Sutro & Co. Inc. and Reich & Co. Inc. are underwriting the offering.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
